Clinical Parkinsonism Related Disorders最新文献

{"title":"Antidiabetic drugs in Parkinson’s disease","authors":"Yoshajandith Aguirre-Vidal ,&nbsp;Sergio Montes ,&nbsp;Ana Carolina Mota-López ,&nbsp;Gabriel Navarrete-Vázquez","doi":"10.1016/j.prdoa.2024.100265","DOIUrl":"10.1016/j.prdoa.2024.100265","url":null,"abstract":"<div><p>This review explores the intricate connections between type 2 diabetes (T2D) and Parkinson’s disease (PD), both prevalent chronic conditions that primarily affect the aging population. These diseases share common early biochemical pathways that contribute to tissue damage. This manuscript also systematically compiles potential shared cellular mechanisms between T2D and PD and discusses the literature on the utilization of antidiabetic drugs as potential therapeutic options for PD. This review encompasses studies investigating the experimental and clinical efficacy of antidiabetic drugs in the treatment of Parkinson’s disease, along with the proposed mechanisms of action. The exploration of the benefits of antidiabetic drugs in PD presents a promising avenue for the treatment of this neurodegenerative disorder.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100265"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000367/pdfft?md5=fd15f18a9d4c09a5e97eb3f8acd864c2&pid=1-s2.0-S2590112524000367-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delirium-onset prodromal Lewy body disease: A series of 5 cases","authors":"Daiki Taomoto ,&nbsp;Yoshiyuki Nishio ,&nbsp;Yousuke Hidaka ,&nbsp;Hideki Kanemoto ,&nbsp;Shun Takahashi ,&nbsp;Manabu Ikeda","doi":"10.1016/j.prdoa.2024.100289","DOIUrl":"10.1016/j.prdoa.2024.100289","url":null,"abstract":"<div><h3>Background</h3><div>Delirium-onset prodromal Lewy body disease (LBD) has been proposed as one of the primary phenotypes of prodromal stages of LBD. The detailed clinical features and biomarker profiles of delirium-onset prodromal LBD have not been well characterized.</div></div><div><h3>Methods</h3><div>Five consecutive cases of delirium-onset prodromal LBD were documented. The diagnosis of prodromal LBD was made based on neuroimaging biomarkers, including dopamine transporter single-photon emission computed tomography (SPECT), cardiac ¹²³I-metaiodobenzylguanidine scintigraphy, and/or brain perfusion SPECT, as well as clinical findings in the post-delirium follow-up periods.</div></div><div><h3>Results</h3><div>In all cases, one or more of the core or supportive clinical features of dementia with Lewy bodies, including rapid eye movement sleep behavior disorder, minor hallucinations, hyposmia, or autonomic dysfunction, were present prior to the onset of delirium. The precipitating factors for delirium were diverse, including surgery, radiation therapy, chemotherapy, and infection. The duration of delirium was prolonged for several months in two cases, whereas it was resolved within a few weeks in the other cases. In most cases, persistent mild cognitive or behavioral symptoms were observed, which were improved with donepezil.</div></div><div><h3>Conclusions</h3><div>Our observations suggest that delirium-onset prodromal LBD may represent the later stages of the prodromal LBD rather than its initial stages. It is possible that delirium in the prodromal stages of LBD may represent subthreshold cognitive fluctuations that are transformed into clinically detectable states by a variety of precipitating factors.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100289"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of optimal vibration dose to treat Parkinson's disease gait symptoms: A clinical trial","authors":"Ingrid Pretzer-Aboff ,&nbsp;R.K. Elswick ,&nbsp;Arnaud Gouelle ,&nbsp;Noah Helm ,&nbsp;GinaMari Blackwell ,&nbsp;Leslie Cloud","doi":"10.1016/j.prdoa.2024.100248","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100248","url":null,"abstract":"<div><h3>Introduction</h3><p>Most people with Parkinson's disease (PD) will experience gait problems. Previous studies demonstrated improved gait and balance after vibration stimulation was applied to the feet of PD patients. However, not all study participants showed improvement, perhaps due to sub-optimal vibration stimulus. Thus far, the optimal frequency and amplitude of vibration for mitigating gait dysfunction in PD have yet to be systematically explored. This study aimed to deliver vibration to the feet of 26 people with PD gait disturbances. We hypothesized that a global frequency, amplitude, and minimum duration of vibration therapy are required to improve PD gait issues.</p></div><div><h3>Methods</h3><p>This was a phase Ib trial to identify optimal vibration parameters. Thirteen participants were recruited at Hoehn &amp; Yahr (H&amp;Y) stage II and 13 participants at stage III. Each group was randomly assigned to different frequency and amplitude settings prescribed by the central composite design methodology. Each participant received vibration for 18 min per walking session, for eight sessions spread over one week.</p></div><div><h3>Results</h3><p>Results showed an optimal response to treatment for frequency (Hz) and amplitude (mm) of vibration based on the Functional Ambulation Performance score for stages II and III. In the H&amp;Y stage II group, stabilization of outcomes occurred after the 4th treatment. This stabilization was not seen in stage III participants.</p></div><div><h3>Conclusions</h3><p>A global frequency and vibration amplitude have been identified for treating PD gait disorders. Patients with more advanced disease may require a longer duration of therapy.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100248"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000173/pdfft?md5=97c93fb562bc1a677ea7f53ace4eb5bd&pid=1-s2.0-S2590112524000173-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140180019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of consciousness coaching in Parkinson’s disease: Experiences and possible impact of holistic coaching","authors":"Lousanne E.J. Tangelder,&nbsp;Ana L. Silva de Lima,&nbsp;Arjonne Laar,&nbsp;Nienke M. de Vries","doi":"10.1016/j.prdoa.2024.100261","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100261","url":null,"abstract":"<div><h3>Background</h3><p>People with a chronic condition such as Parkinson’s disease (PD) struggle with acceptance and finding meaning in life. Consciousness coaching could be a valuable addition in addressing these issues.</p></div><div><h3>Objective</h3><p>We aim to evaluate the user experiences and potential effectiveness of consciousness coaching for people with PD (PwPD).</p></div><div><h3>Methods</h3><p>We performed a pilot randomized controlled trial including PwPD in Hoehn &amp; Yahr stage 1–3. People with cognitive impairments, severe psychiatric disorders, or those who did not have a clear issue to address with consciousness coaching, were excluded. PwPD were randomly allocated to either receiving 6 months of consciousness coaching in addition to usual care or to usual care alone. To explore experiences we performed semi-structured qualitative interviews with all PwPD in the intervention group. Potential effects were explored using questionnaires on quality of life, activities of daily life, self-management and non-motor symptoms at baseline and after 6 months.</p></div><div><h3>Results</h3><p>We included 39 PwPD, 19 participants in the intervention group and 20 in the control group. Based on the interviews, we identified a number of themes and codes. In general PwPD experienced consciousness coaching as confronting but supportive in reaching their goals and in taking more responsibility for their lives. Quantitatively, we did not find a difference between groups for any of the outcomes.</p></div><div><h3>Conclusions</h3><p>Consciousness coaching was considered valuable by most participants in this study and may be an interesting addition to PD treatment. We did not find any effects of the intervention on PD symptoms or quality of life.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100261"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259011252400032X/pdfft?md5=3b993149137640428462a821492bc0c9&pid=1-s2.0-S259011252400032X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hand-foot synkinesis in a patient with phenytoin intoxication","authors":"Gohei Yamada ,&nbsp;Takanari Toyoda ,&nbsp;Eiichi Katada ,&nbsp;Noriyuki Matsukawa","doi":"10.1016/j.prdoa.2024.100237","DOIUrl":"10.1016/j.prdoa.2024.100237","url":null,"abstract":"<div><p>Here we report the first case of phenytoin intoxication that was closely associated with hand-foot synkinesis. This case suggests a close association between cerebellar dysfunction and hand-foot synkinesis. In patients with hand-foot synkinesis, lesions of not only the secondary motor areas but also the cerebellum should be considered.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100237"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000069/pdfft?md5=9415bc7ecfeb849fe6fde9caa50aa249&pid=1-s2.0-S2590112524000069-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139634712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-treatment of freezing of gait in Parkinson’s disease patients using silicone pads to apply Thai acupressure to plantar acupoints: A randomised, controlled trial","authors":"Yuka Miyahara ,&nbsp;Pattamon Panyakaew ,&nbsp;Jiradon Tinuan ,&nbsp;Onanong Phokaewvarangkul ,&nbsp;Chanawat Anan ,&nbsp;Haruki Toriumi ,&nbsp;Roongroj Bhidayasiri","doi":"10.1016/j.prdoa.2024.100254","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100254","url":null,"abstract":"<div><h3>Introduction</h3><p>Freezing of gait (FOG) involves dysfunction of the motor and sensory systems. Peripheral sensory stimuli, including Thai acupressure, can improve proprioceptive function and decrease FOG episodes. Here, we sought to determine the efficacy of acupressure as a self-treatment to alleviate FOG in patients with Parkinson’s disease (PD).</p></div><div><h3>Methods</h3><p>We conducted an open-label, controlled trial of 60 PD patients with FOG while medicated, randomised into two groups: an active-treatment group using silicone pads to apply pressure to plantar acupoints on the head of the big toe and the base of the first metatarsal bone on each foot for 6 s using patient body weight while seated, repeated four times for each acupoint bilaterally, and a sham-treatment group using a similar protocol without the silicone pads. The primary outcome was stride length. Secondary outcomes included FOG episodes, FOG duration, percent duration of FOG to total gait time (%FOG), and gait parameters. A baseline-adjusted analysis of covariance was used to compare outcomes between the two groups.</p></div><div><h3>Results</h3><p>Compared with the sham treatment, the active treatment increased stride length, gait velocity, and cadence (all <em>p</em> &lt; 0.001), and decreased FOG episodes and duration (both <em>p</em> &lt; 0.001), %FOG (<em>p</em> = 0.011), and double-support time (<em>p</em> &lt; 0.001). No adverse effects were noted.</p></div><div><h3>Conclusions</h3><p>Acupressure using silicone pads to stimulate plantar acupoints for self-treatment is a noninvasive, simple, safe way to improve gait and alleviate FOG in patients with PD.</p></div><div><h3>Clinical Trial Registration</h3><p>We registered the study prospectively in the Thai Clinical Trial Registry No. TCTR20200317001.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100254"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000252/pdfft?md5=0c228935185d4950adb022f143ccea33&pid=1-s2.0-S2590112524000252-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRPD frontiers in movement disorders Therapeutics: From evidence to treatment and applications","authors":"Susan L. Perlman","doi":"10.1016/j.prdoa.2024.100255","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100255","url":null,"abstract":"<div><p>The genetic ataxias have no cures and no proven ways to delay progression (no disease-modifying therapies). The acquired ataxias may have treatments that address the underlying cause and may slow or stop progression, but will not reverse damage already sustained. The idiopathic ataxias (of unknown genetic or acquired cause) also have no proven disease-modifying therapies. However, for all patients with ataxia of any cause, there is always something that can be done to improve quality of life—treat associated symptoms, provide information and resources, counsel patient and family, help with insurance and disability concerns, be available to listen and answer the many questions they will have.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100255"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000264/pdfft?md5=3ad21b5beb839dd552ad576cac487c6f&pid=1-s2.0-S2590112524000264-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140950432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do sensorimotor insoles improve gait safety in patients with Parkinson’s disease on a short scale?","authors":"Lisa K. Maurer ,&nbsp;Heiko Maurer ,&nbsp;Manuel König ,&nbsp;Marlena van Munster ,&nbsp;Saskia Haen ,&nbsp;David J. Pedrosa","doi":"10.1016/j.prdoa.2024.100290","DOIUrl":"10.1016/j.prdoa.2024.100290","url":null,"abstract":"<div><h3>Introduction</h3><div>Parkinson’s disease (PD) often leads to gait abnormalities, increasing the risk of falls and affecting daily life. Sensorimotor insoles aim to enhance foot sensitivity, potentially improving gait stability.</div></div><div><h3>Methods</h3><div>This study examined whether there are short-term effects of sensorimotor insoles on neural activation (measured by EEG), kinematic gait parameters (speed, cadence, step length, and step-length variability), and subjective gait stability in PD patients. Sixteen individuals suffering from PD completed a gait task while wearing sensorimotor and placebo insoles, respectively.</div></div><div><h3>Results</h3><div>The results showed no significant changes in kinematic parameters with the sensorimotor insoles. Subjective ratings of gait stability and attentional control of gait improved on average with the sensorimotor insoles, but again did not reach statistical significance. There was no significant reduction in alpha-band activity, indicating no improvement in sensorimotor processing.</div></div><div><h3>Conclusion</h3><div>The immediate impact of sensorimotor insoles on sensorimotor processing and gait characteristics in PD patients remains inconclusive. The small sample size limited the statistical power, highlighting the need for larger studies to comprehensively assess efficacy. Further research should investigate the long-term effects and potential benefits on disability measures in PD patients.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100290"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysphagia is a risk factor of malnutrition in X-linked Dystonia-Parkinsonism","authors":"Tabitha H. Kao ,&nbsp;Perman Gochyyev ,&nbsp;Nutan Sharma ,&nbsp;Jan K. de Guzman ,&nbsp;Melanie Supnet Wells ,&nbsp;Patrick Acuna ,&nbsp;Shasha Li ,&nbsp;Hannah P. Rowe ,&nbsp;Bridget J. Perry","doi":"10.1016/j.prdoa.2024.100282","DOIUrl":"10.1016/j.prdoa.2024.100282","url":null,"abstract":"<div><h3>Introduction</h3><div>Malnutrition is a leading cause of death for persons living with X-linked dystonia-parkinsonism (XDP), a degenerative disease endemic to the Philippines. Difficulty swallowing has been linked to malnutrition in other populations; however, knowledge of this relationship is limited in XDP. As such, the purpose of this study was to determine the association between dysphagia and malnutrition in this population.</div></div><div><h3>Method(s)</h3><div>21 individuals with XDP, 26 controls, and 18 genetic carriers were included in the final data analysis. Spearman’s rank order correlation coefficient was used to determine an association between baseline EAT-10 total scores and 12-month malnutrition status, and multiple linear regression to evaluate the predictive ability of the EAT-10. A baseline EAT-10 score cut-off point predicting 12-month malnutrition status was estimated.</div></div><div><h3>Results</h3><div>For the XDP group, the baseline EAT-10 total scores had a significant negative correlation (<em>r</em> = -0.68, <em>p</em> &lt; 0.001) with and was a significant predictor (<em>p</em> = 0.001) of 12-month BMI. A baseline EAT-10 total score of ≥ 4 predicted malnutrition twelve months after administration (sensitivity = 0.93; specificity = 1; AUC = 0.95).</div></div><div><h3>Discussion</h3><div>Dysphagia, as measured using the EAT-10, was associated with BMI in the XDP population. Additionally, an EAT-10 total score ≥ 4 could predict malnutrition in twelve months after test administration. With these findings, healthcare providers could identify patients with XDP at high risk for malnutrition earlier and provide intervention sooner.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100282"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of MIBG uptake in the major salivary glands between Lewy body disease and progressive supranuclear palsy","authors":"Junya Ebina ,&nbsp;Sunao Mizumura ,&nbsp;Mari Shibukawa ,&nbsp;Harumi Morioka ,&nbsp;Junpei Nagasawa ,&nbsp;Masaru Yanagihashi ,&nbsp;Takehisa Hirayama ,&nbsp;Nobutomo Ishii ,&nbsp;Yukio Kobayashi ,&nbsp;Akira Inaba ,&nbsp;Satoshi Orimo ,&nbsp;Osamu Kano","doi":"10.1016/j.prdoa.2024.100287","DOIUrl":"10.1016/j.prdoa.2024.100287","url":null,"abstract":"<div><h3>Introduction</h3><div>Cardiac sympathetic denervation is specific to Lewy body disease (LBD). In Parkinson’s disease (PD), sympathetic denervation in the major salivary glands (parotid glands [PG] and submandibular glands [SMG]) has been demonstrated by ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy. We compared sympathetic denervation in the MSG between PD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP).</div></div><div><h3>Methods</h3><div>We recruited 81 patients with PD, 12 with DLB, 13 with PSP and 25 with control subjects. We evaluated MIBG uptake in the major salivary glands and heart using a quantitative semi-automatic method. We compared MIBG uptake between PD, DLB, and PSP patients and controls, and we evaluated disease sensitivity and specificity. We compared olfactory function with MIBG uptake between PD and PSP patients.</div></div><div><h3>Results</h3><div>MIBG uptake in the PG and SMG in the delayed phase was significantly lower in PD and DLB patients than in PSP patients and controls. Conversely, MIBG uptake in the major salivary glands and heart was comparable between PD and DLB. Between LBD and non-LBD, MIBG uptake showed 56–100 % specificity in the PG, while it had 55.6–87.5 % sensitivity in the SMG. Between PD and PSP, MIBG uptake in the PG and SMG had higher disease specificity than olfactory function, while the sensitivity of SMG MIBG uptake was comparable to olfactory function.</div></div><div><h3>Conclusion</h3><div>PD and DLB patients showed lower MIBG uptake in the major salivary glands than PSP patients, especially in the delayed phase. MIBG uptake in the major salivary glands may differentiate PD from hyposmic PSP.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100287"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}